TG Therapeutics TGTX · NASDAQ
$53.97 -3.63% (-$2.03)
Summary
62 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 55 USD is left as net profit.
- Revenue grew by 505% a year over the last 3 years.
- It earns 43 USD a year on every 100 USD of invested capital.
- Analysts expect revenue to grow by 56% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- It missed profit estimates 6 times in the last 8 quarters.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 18.7 USD for 1 USD of yearly profit. Over the last five years it was 139.1 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 427% a year over 5 years. Over the last 3 years it grew by 505% a year. For the next fiscal year analysts expect revenue to grow by 56%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 18 USD
- Research and development 28 USD
- Sales and administration 37 USD
- Taxes and other -38 USD
- Net profit 55 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 55 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 1
- Sell 1
Today's price within the analysts' price targets
The average target of $80.5 is 49% above today's price. 85% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 98%
- Royalty 0.9%
- Other Revenue 0.6%
- License Revenue 0.0%
By region
- Worldwide 99%
- International 1.2%
Product brings in 98% of revenue.
Segments in detail